Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

TRIDENT-2 study evaluates repotrectinib combined with trametinib in KRAS G12D mutant solid tumors

Aug. 17, 2021

Phase II study initiated to assess aspacytarabine in AML and MDS patients

Aug. 17, 2021

LAVA Therapeutics cleared to initiate clinical trial of LAVA-1207

Aug. 16, 2021

Phase Ib data reported for ITPP in patients with hepatopancreatobiliary tumors

Aug. 16, 2021

Beijing Jacobio Pharmaceuticals presents new AURK1 inhibitors

Aug. 16, 2021

Kangpu Biopharmaceuticals divulges CRBN-binding isoindolines

Aug. 16, 2021

Mustang Bio and Mayo Clinic collaborate on development of novel CAR T technology

Aug. 13, 2021

VYNE and In4Derm enter licence agreement for discovery and development of BET inhibitor platform

Aug. 13, 2021

SSAO inhibitors identified at Shanghai Ennova Biopharmaceutical, Ennovabio Pharmaceuticals

Aug. 13, 2021

B-Raf, MEK1 inhibitors discovered at Chugai

Aug. 13, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...